Trial Profile

Phase 1b/3 Multicenter Study of Oprozomib, Pomalidomide, and Dexamethasone in Primary Refractory or Relapsed and Refractory Multiple Myeloma Subjects

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 28 Apr 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Oprozomib (Primary) ; Dexamethasone; Pomalidomide
Indications Multiple myeloma
Focus Adverse reactions
Sponsors Amgen; Onyx Pharmaceuticals

Most Recent Events

31 Mar 2021 Status changed from completed to discontinued.
03 May 2019 Status changed from active, no longer recruiting to completed.
12 Feb 2019 Planned End Date changed from 28 Feb 2019 to 30 Apr 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com